MK-4208 for Chronic Myeloid Leukemia Treatment
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
Recruiting
Phase 1
Phase 2
Interventional Study
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic Myeloid Leukemia, Chronic Phase
Chronic Myeloid Leukemia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 330 (estimated)
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
Who this trial is looking for
This trial is looking for people with chronic myeloid leukemia who have already tried other treatments without success. Participants will help researchers learn about the safety of a new medication called MK-4208 at different doses.
Are You a Good Fit for This Trial?
You may be able to join if
- I have a diagnosis of chronic myeloid leukemia in the chronic phase.
- I have received treatment with at least one prior tyrosine kinase inhibitor.
- I have not had success or tolerated my previous treatments well.
- I have an ECOG performance status score of 0 to 2.
- I have adequate organ function.
- I have completed previous anticancer therapy without significant ongoing side effects.
You may not be able to join if
- I have had any systemic antineoplastic therapy in the last 7 days.
- I have not resolved all associated clinically significant toxicity from previous treatments.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
Researchers are looking for a new way to treat a blood cancer called chronic myeloid leukemia (CML). Researchers want to learn if MK-4208 (Tern-701) can treat this type of blood cancer.
The goal of this study is to learn about the safety of different doses (amounts) of MK-4208 (Tern-701) and if people tolerate them. Researchers also want to find the highest dose of MK-4208 (Tern-701) that people …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Key Inclusion Criteria:
Inclusion Criteria include but are not limited to:
* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
* Have an established cytopathologically confirmed diagnosis of breakpoint cluster region::Abelson (BCR-ABL1) positive Chronic Myeloid L…
Contacts